Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States DOI Creative Commons

Ahnika Kline,

Ana G. Cobián-Güemes, Jennifer Yore

и другие.

Antibiotics, Год журнала: 2025, Номер 14(6), С. 553 - 553

Опубликована: Май 29, 2025

The resurgence of phage therapy in Western societies has been direct response to recent increases antimicrobial resistance (AMR) that have ravaged many societies. While as a concept around for over 100 years, it largely replaced by antibiotics due their relative ease use and predictability spectrum activity. Now become less reliable greater antibiotic microbiome disruption, once again viable promising alternative, but is not without its challenges. Much like the development antibiotics, with deployment therapeutics there will be simultaneous need diagnostics clinical laboratory. This review provides an overview current challenges widespread adoption focus on diagnostic Current barriers include lack standard methodology quality controls susceptibility testing selection, absence phage-antibiotic synergy testing, methods assay activity biofilms. Additionally, are number lab-specific administrative regulatory including pharmacokinetic (PK) pharmacodynamic (PD) assays, account changes phages after passaging, guidance what required agency approvals how broad approval apply, increased lab personnel or automation work large libraries against bacteria isolates.

Язык: Английский

Advances in Engineered Phages for Disease Treatment DOI Open Access
Xiaolin Hou,

Zhai Lin,

Laiying Fu

и другие.

Small Methods, Год журнала: 2025, Номер unknown

Опубликована: Фев. 11, 2025

Abstract Phage therapy presents a promising solution for combating multidrug‐resistant (MDR) bacterial infections and other bacteria‐related diseases, attributed to their innate ability target lyse bacteria. Recent clinical successes, particularly in treating MDR‐related respiratory post‐surgical infections, validated the therapeutic potential of phage therapy. However, complex microenvironment within human body poses significant challenges activity efficacy vivo. To overcome these barriers, recent advances engineering have aimed enhance targeting accuracy, improve stability survivability, explore synergistic combinations with modalities. This review provides comprehensive overview therapy, emphasizing application engineered phages antibacterial tumor vaccine development. Furthermore, highlights current future trends advancing toward broader applications.

Язык: Английский

Процитировано

1

Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control—A Narrative Review DOI Creative Commons
A Sandu, Mariana Carmen Chifiriuc, Corneliu Ovidiu Vrâncianu

и другие.

Infectious Diseases and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Язык: Английский

Процитировано

0

Phage therapy: a promising approach for Staphylococcus aureus diabetic foot infections DOI Creative Commons
Lucile Plumet, Chloé Magnan, Denis Costechareyre

и другие.

Journal of Virology, Год журнала: 2025, Номер unknown

Опубликована: Май 14, 2025

ABSTRACT Diabetic foot infections (DFIs), predominantly caused by Staphylococcus aureus , pose a significant healthcare challenge with severe consequences, including amputation. Phage therapy, which utilizes bacteriophages to specifically target bacterial pathogens, has emerged as promising alternative conventional antibiotic treatments. This review evaluates the efficacy of phage therapy complementary treatment for DFIs S. synthesizing evidence from preclinical and clinical studies while addressing limitations challenges associated current research. The analysis highlights results diabetic animal models, demonstrating effective load reduction improved wound healing. Clinical case reports series further underline improvements in infection management ulcer healing, no major adverse effects reported. Ongoing trials are also discussed, offering insights into study parameters evaluating potential safety -related DFIs. While collected data highlight valuable complement traditional treatments, particularly managing antibiotic-resistant infections, research is essential address existing limitations, gaps long-term standardization. With continued investigation, holds alleviate burden improve patient outcomes.

Язык: Английский

Процитировано

0

Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States DOI Creative Commons

Ahnika Kline,

Ana G. Cobián-Güemes, Jennifer Yore

и другие.

Antibiotics, Год журнала: 2025, Номер 14(6), С. 553 - 553

Опубликована: Май 29, 2025

The resurgence of phage therapy in Western societies has been direct response to recent increases antimicrobial resistance (AMR) that have ravaged many societies. While as a concept around for over 100 years, it largely replaced by antibiotics due their relative ease use and predictability spectrum activity. Now become less reliable greater antibiotic microbiome disruption, once again viable promising alternative, but is not without its challenges. Much like the development antibiotics, with deployment therapeutics there will be simultaneous need diagnostics clinical laboratory. This review provides an overview current challenges widespread adoption focus on diagnostic Current barriers include lack standard methodology quality controls susceptibility testing selection, absence phage-antibiotic synergy testing, methods assay activity biofilms. Additionally, are number lab-specific administrative regulatory including pharmacokinetic (PK) pharmacodynamic (PD) assays, account changes phages after passaging, guidance what required agency approvals how broad approval apply, increased lab personnel or automation work large libraries against bacteria isolates.

Язык: Английский

Процитировано

0